David M. O'Malley, MD, The Ohio State University

David M. O'Malley, MD discusses the utility of chemoimmunotherapy in ovarian cancer.

Dr. O’Malley on the Efficacy of Pembrolizumab in Advanced Ovarian Cancer

July 8th 2021

David M. O'Malley, MD, discusses the efficacy of pembrolizumab in patients with advanced ovarian cancer.

The Future of Endometrial Cancer Treatment

Bradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

June 4th 2021

Experts give insight on what they are looking forward to in the endometrial cancer space.

A Look at Surgical Innovations in EC

Bradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

June 4th 2021

Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.

Novel Targets of Interest in EC

Bradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

June 4th 2021

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

Insight on Ongoing Trials in EC

Bradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

June 4th 2021

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.

Incorporating Molecular Features into Choosing Adjuvant Therapy

Bradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

June 4th 2021

Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.

Therapeutic Sequencing in Endometrial Cancer

Bradley J. Monk, MD, FACS, FACOG, University of Arizona, Creighton University, & Arizona Oncology Practice of US Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

June 4th 2021

Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.

Managing AEs With Pembrolizumab and Lenvatinib

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

June 1st 2021

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.

Experience in Using Pembrolizumab + Lenvatinib in Advanced Endometrial Cancer

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

June 1st 2021

Experts give insight on their clinical use of pembrolizumab-lenvatinib. They highlight dose adjustments and the importance of the increased knowledge of adverse events.

A Discussion on the Study 309/KEYNOTE-775 Data

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

May 25th 2021

Key opinion leaders discuss the presented data from Study 309/KEYNOTE-775, highlighting patient reported outcomes, safety, and dosing.

Results from Study 309/KEYNOTE-775

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

May 25th 2021

Vicky Makker, MD, presents the results from Study 309/KEYNOTE-775, as well as key safety findings.

Study 309/KEYNOTE-775 Trial Design

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

May 18th 2021

Vicky Makker, MD, walks through the trial design of Study 309/KEYNOTE-775.

Therapeutic Approaches in Endometrial Cancer

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

May 18th 2021

Experts review optimal approaches to treatment in advanced endometrial cancer, touching on clinical trial data.

Biomarker Testing and Multidisciplinary Approaches in EC

Bradley J. Monk, MD, FACS, FACOG, University of Arizona;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

May 11th 2021

Key opinion leaders share their thoughts on biomarker testing and multidisciplinary approaches for endometrial cancer at their institutions globally.

Heterogeneity of Endometrial Cancer

Bradley J. Monk, MD, FACOG, FACS, University of Arizona;Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia;Vicky Makker, MD, Memorial Sloan Kettering Cancer Center;Domenica Lorusso, MD, PhD;David M. O'Malley, MD, The Ohio State University

May 11th 2021

Experts in gynecologic cancer discuss the heterogeneity of endometrial cancer..

Promising Novel Targets for Endometrial Cancer Management

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

February 4th 2021

Novel Strategies in Development for EC Management

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

February 4th 2021

Therapy Sequencing Through Multiple Lines of Therapy in EC

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

February 4th 2021

Impact of Pembrolizumab/Lenvatinib Approval in EC

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

February 4th 2021

Safety/Efficacy Results From EC Cohort of KEYNOTE-146

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

February 4th 2021

Rationale for Combination Therapy in Advanced EC

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

February 4th 2021

GARNET Clinical Trial Regimen in Advanced Disease

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

February 4th 2021

Second-Line Checkpoint Inhibitor for MSI-H Disease

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

February 4th 2021

Adjuvant Chemotherapy +/- Radiotherapy: Recent Data

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

February 4th 2021

Treatment Challenges: Advanced Endometrial Cancer

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

February 4th 2021

Genomic Assessments for Metastatic Disease

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

January 29th 2021

Endometrial Cancer Incidence and Risk Classification

Kathleen Moore, MD, Stephenson Cancer Center;David M. O'Malley, MD, The Ohio State University

January 29th 2021

Future of Advanced Endometrial Cancer

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

Novel Targets for Advanced Endometrial Cancer

Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine

January 4th 2021

David M. O'Malley, MD, The Ohio State University

Articles

Latest Updated Articles

Latest Conference Coverage